Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS) - Concepedia

Concepedia

Publication | Open Access

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)

DOI Full Paper Access

26

Citations

16

References

2023

Year

Richard B. Warren, Lars E. French, Andrew Blauvelt, Richard G. Langley, Alexander Egeberg, Ulrich Mrowietz, H.J.A. Hunter, Melinda Gooderham, Per Soelberg Soerensen, Philippe Andrès,

Journal of the American Academy of Dermatology

References

	Year	Citations

Page 1